Eli Lilly and (NYSE: LLY) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Eli Lilly and to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, dividends, institutional ownership and valuation.

Insider & Institutional Ownership

75.7% of Eli Lilly and shares are owned by institutional investors. Comparatively, 43.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Eli Lilly and shares are owned by company insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Eli Lilly and pays out 98.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 65.6% of their earnings in the form of a dividend. Eli Lilly and has increased its dividend for 2 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Eli Lilly and and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and 1 6 10 0 2.53
Eli Lilly and Competitors 847 3784 6815 185 2.54

Eli Lilly and presently has a consensus target price of $90.94, indicating a potential upside of 10.98%. As a group, “Pharmaceuticals” companies have a potential upside of 23.22%. Given Eli Lilly and’s peers stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and has less favorable growth aspects than its peers.

Risk & Volatility

Eli Lilly and has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Eli Lilly and’s peers have a beta of 0.95, indicating that their average share price is 5% less volatile than the S&P 500.


This table compares Eli Lilly and and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eli Lilly and 9.90% 30.27% 10.82%
Eli Lilly and Competitors -2,859.64% -1,952.92% -9.21%

Valuation & Earnings

This table compares Eli Lilly and and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Eli Lilly and $22.00 billion $5.99 billion 38.83
Eli Lilly and Competitors $8.08 billion $2.63 billion -0.02

Eli Lilly and has higher revenue and earnings than its peers. Eli Lilly and is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


Eli Lilly and beats its peers on 9 of the 15 factors compared.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.